Holen Sie sich die Stockscreener-App
20.37
4.25%
0.83
Handel nachbörslich:
20.37
Schlusskurs vom Vortag:
$19.54
Offen:
$19.5
24-Stunden-Volumen:
1.91M
Relative Volume:
1.21
Marktkapitalisierung:
$2.52B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-6.5922
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+7.27%
1M Leistung:
-11.40%
6M Leistung:
+92.90%
1J Leistung:
+106.17%
1-Tages-Spanne:
$19.50
$20.44
1-Wochen-Bereich:
$18.52
$21.20
52-Wochen-Spanne:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
20.37 | 2.42B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Call Highlights: S - GuruFocus
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: Arcus Biosciences beats EPS expectations in Q4 2025 - Investing.com Nigeria
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
RCUS: Casdatifan delivers superior efficacy in RCC, driving strong financials and market potential - TradingView
Arcus Biosciences Files For Mixed Shelf - TradingView
RCUS: 2025 net loss widened to $353M on $247M revenue; $1.0B cash supports late-stage pipeline - TradingView
Arcus Biosciences, Inc. SEC 10-K Report - TradingView
Arcus Biosciences Earnings Review: Q4 Summary - Benzinga
Arcus Biosciences Provides Pipeline Update on Its Clinical-Stage Investigational Molecules and Discovery Programs - marketscreener.com
Arcus Biosciences in spotlight: Kidney drug trial results at stake - Investing.com India
Can Arcus Biosciences Inc stock double in the next yearJuly 2025 Decliners & Real-Time Buy Zone Alerts - baoquankhu1.vn
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Report Preview: Wh - GuruFocus
Arcus Biosciences (NYSE:RCUS) Shares Up 10.1%Here's Why - MarketBeat
Market Catalysts: Is Arcus Biosciences Inc in a long term uptrendJuly 2025 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn
Arcus Biosciences (RCUS) Showcases Promising Data for Casdatifan in Cancer Study - GuruFocus
Late-line kidney cancer patients top a year without progression on Arcus drug - Stock Titan
Arcus Biosciences’ cancer drug gets orphan drug status - MSN
Investment Report: Can Arcus Biosciences Inc disrupt its industryTreasury Yields & Consistent Growth Stock Picks - baoquankhu1.vn
Is Arcus Biosciences Inc. stock worth buying before Fed actionWeekly Trade Recap & High Conviction Buy Zone Picks - mfd.ru
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
Aberdeen Group plc Makes New $4.42 Million Investment in Arcus Biosciences, Inc. $RCUS - MarketBeat
Earnings Beat: What’s Arcus Biosciences Inc.’s historical returnTrade Entry Report & Community Supported Trade Ideas - mfd.ru
Arcus Biosciences (RCUS) Stock Analysis: Exploring a 65% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Here's What Analysts Think About Arcus Biosciences (RCUS) - Finviz
Here’s What Analysts Think About Arcus Biosciences (RCUS) - Insider Monkey
A Look At Arcus Biosciences (RCUS) Valuation After Wells Fargo Downgrade And Shifting Analyst Sentiment - Yahoo Finance
How Arcus Biosciences Inc. (RCUS) Affects Rotational Strategy Timing - Stock Traders Daily
What’s Arcus Biosciences Inc.’s historical returnQuarterly Growth Report & Step-by-Step Trade Execution Guides - mfd.ru
Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment - MSN
Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
How cyclical is Arcus Biosciences Inc.’s revenue streamWeekly Trade Report & High Return Trade Opportunity Guides - mfd.ru
RCUS: Wells Fargo Downgrades Arcus Biosciences, Lowers Price Tar - GuruFocus
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
What Analysts Are Saying About Arcus Biosciences Stock - Benzinga
Candriam S.C.A. Takes $5.15 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
Cancer drug developer Arcus sets Feb. 25 call on 2025 results - Stock Titan
Is Arcus Biosciences Inc. stock a smart retirement pickQuarterly Investment Review & Safe Capital Investment Plans - mfd.ru
Arcus Advances Quemliclustat With New Phase 1 Study: What Investors Should Know - TipRanks
Arcus Biosciences stock hits 52-week high at $21.03 By Investing.com - Investing.com South Africa
Arcus Biosciences stock hits 52-week high at $21.03 - Investing.com
Arcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street Zen - MarketBeat
(RCUS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High? - sharewise.com
Aug Decliners: How correlated is Arcus Biosciences Inc to the S P500Portfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Arcus Biosciences, Inc. (RCUS): Analyst Consensus Signals 51% Upside Potential Amid Robust Clinical Pipeline - DirectorsTalk Interviews
What is Arcus Biosciences Inc.’s valuation compared to sectorTrend Reversal & Capital Efficient Trade Techniques - mfd.ru
Arcus Biosciences Grants Stock Options to Employees - intellectia.ai
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):